Rockville, Maryland - September 17, 2003 - GlycoMimetics, Inc. (GMI) today announced the appointment of Franklin H. Top, Jr., M.D. and John J. Baldwin, Ph.D. to its Board of Directors. Dr. Top currently is Medical Director of MedImmune, Inc., and is a former Director of Walter Reed Army Institute of Research. Dr. Baldwin is a Co-Founder, President, and Chief Scientific Officer of Concurrent Pharmaceuticals, a co-founder of Pharmacopeia, Inc., and a thirty-three year veteran of Merck & Co.

"Doctors Baldwin and Top bring a wealth of critical expertise," said Rachel King, GMI CEO. "Their commitment is in itself an important validation of our approach. I'm looking forward to working with each of them."

"GMI is well-positioned to develop therapies based on the latest advancements in glycobiology," said Dr. Top. "The science is promising, and I'm excited about this opportunity."

"The company has an impressive foundation," added Dr. Baldwin. "Both the management team and the syndicate of investors have compelling track records. The company is poised to produce a broad range of drug candidates in a number of major markets."

Dr. Baldwin co-founded Concurrent Pharmaceuticals in May 2001. Prior to that, he spent nine years at Pharmacopeia, Inc., where he was a co-founder and served as Chief Scientific and Technology Officer. Prior to Pharmacopeia, Dr. Baldwin was a Distinguished Senior Scientist at Merck & Co., where he spent 33 years in various scientific and management positions. Dr. Baldwin received his B.S. in chemistry from the University of Delaware and his Ph.D. in organic chemistry from the University of Minnesota.

Dr. Top joined MedImmune in June 1988 as Executive Vice President, was elected to its Board of Directors in July 1988 and became the company's Medical Director in June 1990. From 1987 to 1988, Dr. Top served as Senior Vice President for Clinical and Regulatory Affairs at Praxis Biologics. Prior to 1987, Dr. Top served for 22 years in the U.S. Army Medical Research and Development Command, where he was appointed Director, Walter Reed Army Institute of Research in 1983. Dr. Top holds a Doctorate of Medicine cum laude and a Bachelor of Science degree in biochemistry from Yale University.

About GMI
GMI capitalizes on advances in the field of glycobiology by developing small molecule drugs that mimic the action of carbohydrates. GMI acquired the assets of GlycoTech and builds upon a platform technology for designing and screening carbohydrate mimics which was developed over a collaboration between GlycoTech and Ciba-Geigy (later Novartis). GMI owns or has exclusive licenses to 15 issued U.S. patents.

# # #

12.09.07: GMI Presents Results of Lead Compound in Animal Models of Vaso-Occlusive Crisis at ASH.

07.19.07: GMI Highlights Advances in Lead Drug Candidate at International Conference.

06.23.06: GMI Closes $15.4-million Series B.

09.02.05: GMI to Present New Data on Lead Compounds at International Symposium

08.15.05: Washington Business Journal - GlycoMimetics chief named to biotech institute's board

07.18.05: Washington Business Journal - GlycoMimetics CEO Named to bio group's board.

05.20.05: Windhover Start-up Magazine - Glycobiology's Second Wave

12.23.04: GMI Sponsors, Presents at Annual Glycobiology Conference

08.13.04: Baltimore Business Journal - Montgomery biotech GlycoMimetics taps into Baltimore VCs, state fund

08.05.04: GMI Secures $5.1-million in Series A Extension

03.26.04: Washington Business Journal: Some relief for biotech's financial headaches*

03.15.04: The Washington Post - GMI's research taps troublesome carbohydrates to combat disease *

01.07.04: Red Herring Magazine - Venture Capitol*

11.03.03: Washington Post - Venture Funding Dips in 3rd Quarter *

10.28.03: Ginsburg Memorial Symposium Announced

9.20.03: Recap Magazine - Glycobiology: Biotech's New Sweet Spot *

09.17.03: GMI Announces Key Adds to BOD

06.06.03: The Business Gazette - Rockville biotech company to put new financing to use *

05.22.03: GMI Closes $4.3M Seed Round

* The article will open in a new browser window.